MEN1611

DRUG3 trials

Sponsors

Menarini Group, MedSIR

Conditions

Advanced Breast CancerAdvanced or Metastatic Breast CancerBreast CancerMetastatic Breast CancerMetastatic Colorectal Cancer

Phase 1

MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

CompletedNCT03767335

Menarini GroupAdvanced or Metastatic Breast Cancer

Start: 2018-11-13End: 2024-02-23Updated: 2025-06-26

MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

CompletedNCT04495621

Menarini GroupMetastatic Colorectal Cancer

Start: 2020-07-20End: 2024-02-27Updated: 2025-05-01

Phase 2

PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin

Active, not recruitingNCT05810870

MedSIRAdvanced Breast Cancer, Breast Cancer, Metastatic Breast Cancer

Start: 2023-05-24End: 2027-07-01Updated: 2026-03-10

Related Papers

Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer

Breast Cancer Research and Treatment2023-03-137 citations

Abstract 1376: Dosing frequency/PD/efficacy relationship of MEN1611 in HER2 amplified, PIK3CA mutated, and refractory to Trastuzumab xenograft model of breast cancer

Cancer Research2021-07-01

B-PRECISE-01 Study: A phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer.

Journal of Clinical Oncology2019-05-205 citations